Shares of Oxford BioMedica plc (LON:OXB) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $633.33 and traded as low as $599.56. Oxford BioMedica shares last traded at $601.00, with a volume of 90,917 shares trading hands.
Several equities analysts recently issued reports on the stock. Peel Hunt reissued a “buy” rating on shares of Oxford BioMedica in a report on Monday, November 4th. Liberum Capital reissued a “buy” rating on shares of Oxford BioMedica in a report on Friday, November 15th.
The stock has a market capitalization of $461.45 million and a P/E ratio of -51.81. The firm’s fifty day moving average is GBX 560.30 and its 200-day moving average is GBX 633.33. The company has a current ratio of 2.21, a quick ratio of 1.80 and a debt-to-equity ratio of 10.55.
In related news, insider Martin Diggle bought 17,953 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was bought at an average cost of GBX 577 ($7.54) per share, with a total value of £103,588.81 ($135,357.13). Also, insider Lorenzo Tallarigo bought 482 shares of the company’s stock in a transaction on Wednesday, September 25th. The stock was bought at an average cost of GBX 554 ($7.24) per share, with a total value of £2,670.28 ($3,489.19). Insiders have purchased a total of 18,905 shares of company stock valued at $10,893,339 over the last three months.
About Oxford BioMedica (LON:OXB)
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.